Adlai Nortye Group Ltd. (NASDAQ:ANL)
| Market Cap | $453.83M+506.4% |
| Revenue (ttm) | $19.68M |
| Net Income | -$22.53M+47.1% |
| EPS | -$1.95+46.4% |
| Shares Out | 53.08M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 380,645 |
| Open | $8.79 |
| Previous Close | $9.06 |
| Day's Range | $8.36 - $8.98 |
| 52-Week Range | $0.88 - $17.25 |
| Beta | 1.16 |
| Analysts | Buy |
| Price Target | $37.33(+336.61%) |
| Earnings Date | Mar 3, 2027 |
About ANL
Adlai Nortye Ltd. (ANL) is a clinical-stage biotechnology firm dedicated to the research and development of innovative pharmaceutical products. Their flagship compound, AN2025, a pan-phosphoinositide 3-kinase inhibitor, is currently undergoing Phase III clinical trials. It is being investigated as a potential treatment for recurrent or metastatic head and neck squamous cell carcinomas. The company's pipeline also features AN0025, a small molecule prostaglandin E receptor 4 antagonist designed to modulate the tumor microenvironment. This candidate is in Phase Ib clinical trials, exploring its efficacy in treating various conditions, including: recurrent non-small cell lung cancer; urothelial cancer (post-anti-PD-1/PD-L1 treatments); recurrent triple-negative breast cancer; microsatellite stable colorectal cancer; and cervical cancer (following standard-of-care treatments). Additionally, ANL is developing AN4005, an oral small-molecule PD-L1 inhibitor. This drug, which is in Phase I clinical trials, aims to induce and stabilize PD-L1 dimerization to disrupt the interaction between PD-1 and PD-L1. Beyond their clinical programs, Adlai Nortye has early-stage research candidates such as AN8025, a multifunctional antibody that acts as a modulator of T cells and antigen-presenting cells, and AN9025, an oral small molecule pan-KRAS inhibitor. Established in 2004, the company's headquarters are situated in Grand Cayman, Cayman Islands.
What Are Insiders Doing?
View the trades behind this meter — each links to its SEC Form 4 →
Open-market Form 4 purchases (code P) vs sales (code S) on file for this company. Grants, option exercises and tax withholdings are excluded. Informational only.
Analyst consensus
1 firm rating ANL in the last 3 months, one vote each. Issuer-paid research is not counted.
Next catalysts
- Mar 3, 2027Earnings report
$ANL stock is featured in our Insider Score Rankings, and Insider Trades datasets.
→ All Stock ListsRecently reported changes in ANL holdings by institutional investors
Latest 0 13F filings · Source: SEC EDGAR
View all institutional owners →Insider Trading
Quarterly net insider trading by ANL's directors and management
Source: SEC EDGAR (Form 4)
Corporate Lobbying
ANL Estimated quarterly lobbying spending
Source: U.S. Senate LDA
U.S. Patents
New ANL patent grants
Source: USPTO Open Data Portal
Government Contracts
Estimated quarterly amount awarded to ANL from public contracts
Source: USAspending.gov
Top ETF Holders
ETFs with the largest estimated holdings in ANL
| CANCTema Oncology ETF | $889.76K |
| EWXState Street SPDR S&P Emerging Markets Small Cap ETF | $262.74K |
| BBCVirtus Biotech Clinical Trials ETF | $234.36K |
| GXCState Street SPDR S&P China ETF | $65.23K |
Estimated from each fund’s disclosed top holdings × AUM
Bull Case vs Bear Case
AI-generated from ANL’s recent data — informational, not investment advice
What’s Behind the Score
Recent Insider Activity
Insider Score Trend Over Time
-47.0 since Aug 27Composite Insider Score (0–100) recomputed on each scoring run from live SEC Form 4 data.
